BBS7

Across TCGA pan-cancer cohorts, BBS7 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BBS7 data layer compared with 29 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher BBS7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BBS7 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, STAD, and LIHC are the cancer types where BBS7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.164	0.702	.001	33	view →
STAD	OS	Median	II,III,IV	0.184	0.710	.002	12	view →
LIHC	OS	Median	All	0.063	0.781	<.001	12	view →
COAD	DFS	Median	All	0.140	0.781	<.001	9	view →
UCEC	DFS	Median	All	0.922	0.621	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BBS7–ESCA (OS)

Open the ESCA breakdown →